Aurinia Pharmaceuticals stock gets lift from higher 2026 outlook
Published on 11/05/2026 at 02:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSResults Lift Aurinia Outlook
- Third-quarter revenue rose 14 percent year over year to USD 83.7 million.
- Net income was USD 31.7 million, while nine-month net income increased 35 percent to USD 103.5 million.
- Aurinia advanced the PRESERVE Phase 4 study and continued development of aritinercept in autoimmune diseases.
Aurinia Pharmaceuticals reported stronger year-to-date revenue and raised its 2026 outlook in results released on October 30, 2026. The company said third-quarter revenue increased 14 percent year over year, while the updated forecast points to continued commercial momentum for LUPKYNIS.
Revenue Growth Supports Guidance
According to StockTitan's summary of the 10-Q, Aurinia generated USD 83.7 million in revenue for the three months ended September 30, 2026, compared with USD 73.5 million a year earlier. LUPKYNIS net product sales rose 12 percent to USD 79.4 million, and license, collaboration and royalty revenue increased 54 percent to USD 4.3 million.
Net income was USD 31.7 million, broadly unchanged from the prior-year quarter, while diluted earnings per share remained at USD 0.23. For the first nine months, revenue reached USD 244.6 million and net income rose to USD 103.5 million from USD 76.4 million.
Pipeline Adds Development Focus
Aurinia increased its 2026 total revenue guidance from a range of USD 315 million to USD 325 million to USD 325 million to USD 330 million. The company narrowed its LUPKYNIS net product sales outlook to USD 310 million to USD 315 million from USD 305 million to USD 315 million.
The company also initiated PRESERVE, a Phase 4 study testing LUPKYNIS combinations in lupus nephritis. The planned study covers approximately 150 patients at approximately 50 US sites, with complete renal response at six months as the primary endpoint. Aritinercept development is progressing in four potential indications.
Aurinia Pharmaceuticals stock traded at EUR 15.25 on Lang & Schwarz at 23:00 Berlin time on Wednesday, November 4, 2026. Investors can follow the real-time quote of Aurinia Pharmaceuticals stock.
Autoimmune Drug Specialist
Aurinia Pharmaceuticals is a Canadian biopharmaceutical company focused on therapies for autoimmune diseases with high unmet medical needs. Its commercial product is LUPKYNIS, an oral treatment for adults with active lupus nephritis, while its pipeline includes the dual BAFF and APRIL inhibitor aritinercept. The company is based in Edmonton, Alberta, and its shares trade on the Nasdaq Global Market under AUPH.
Aurinia Pharmaceuticals at a Glance
- Company: Aurinia Pharmaceuticals Inc.
- ISIN: CA05156V1022
- Ticker: AUPH
- Home exchange: Nasdaq Global Market
- Lang & Schwarz quote: EUR 15.25 on November 4, 2026 at 23:00 Berlin time
- Third-quarter revenue: USD 83.7 million for the period ended September 30, 2026
- 2026 revenue guidance: USD 325 million to USD 330 million
Broader sentiment for US biotechnology shares can be followed through the S&P 500 market environment.
